WO2024040027A3 - Phlip®-mediated delivery of sting agonists - Google Patents

Phlip®-mediated delivery of sting agonists Download PDF

Info

Publication number
WO2024040027A3
WO2024040027A3 PCT/US2023/072169 US2023072169W WO2024040027A3 WO 2024040027 A3 WO2024040027 A3 WO 2024040027A3 US 2023072169 W US2023072169 W US 2023072169W WO 2024040027 A3 WO2024040027 A3 WO 2024040027A3
Authority
WO
WIPO (PCT)
Prior art keywords
phlip
mediated delivery
sting agonists
compositions
sting
Prior art date
Application number
PCT/US2023/072169
Other languages
French (fr)
Other versions
WO2024040027A2 (en
Inventor
Yana K. Reshetnyak
Oleg A. Andreev
Donald M. Engelman
Anna Moshnikova
Original Assignee
University Of Rhode Island Board Of Trustees
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Rhode Island Board Of Trustees, Yale University filed Critical University Of Rhode Island Board Of Trustees
Publication of WO2024040027A2 publication Critical patent/WO2024040027A2/en
Publication of WO2024040027A3 publication Critical patent/WO2024040027A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions comprising a pHLIP® peptide linked to a STING agonist, pharmaceutical compositions thereof, and methods of treatment using such compositions are disclosed herein.
PCT/US2023/072169 2022-08-15 2023-08-14 Phlip®-mediated delivery of sting agonists WO2024040027A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263371486P 2022-08-15 2022-08-15
US63/371,486 2022-08-15

Publications (2)

Publication Number Publication Date
WO2024040027A2 WO2024040027A2 (en) 2024-02-22
WO2024040027A3 true WO2024040027A3 (en) 2024-03-28

Family

ID=89942374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/072169 WO2024040027A2 (en) 2022-08-15 2023-08-14 Phlip®-mediated delivery of sting agonists

Country Status (1)

Country Link
WO (1) WO2024040027A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180117183A1 (en) * 2016-09-22 2018-05-03 Rhode Isalnd Council on Postsecondary Education FLUORESCENT COMPOUND COMPRISING A FLUOROPHORE CONJUGATED TO A pH-TRIGGERED POLYPEPTIDE
US20180369425A1 (en) * 2017-06-09 2018-12-27 Rhode Island Council On Postsecondary Education LINKED AND OTHER pH-TRIGGERED COMPOUNDS
US20220088208A1 (en) * 2019-01-28 2022-03-24 University Of Rhode Island Board Of Trustees Phlip®-mediated intracellular delivery of immuno-stimulatory compounds
WO2022066650A1 (en) * 2020-09-22 2022-03-31 Memorial Sloan Kettering Cancer Center Radiolabeled ligands for targeted pet/spect imaging and methods of their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180117183A1 (en) * 2016-09-22 2018-05-03 Rhode Isalnd Council on Postsecondary Education FLUORESCENT COMPOUND COMPRISING A FLUOROPHORE CONJUGATED TO A pH-TRIGGERED POLYPEPTIDE
US20180369425A1 (en) * 2017-06-09 2018-12-27 Rhode Island Council On Postsecondary Education LINKED AND OTHER pH-TRIGGERED COMPOUNDS
US20220088208A1 (en) * 2019-01-28 2022-03-24 University Of Rhode Island Board Of Trustees Phlip®-mediated intracellular delivery of immuno-stimulatory compounds
WO2022066650A1 (en) * 2020-09-22 2022-03-31 Memorial Sloan Kettering Cancer Center Radiolabeled ligands for targeted pet/spect imaging and methods of their use

Also Published As

Publication number Publication date
WO2024040027A2 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
Chou et al. Short, multiple-stranded β-hairpin peptides have antimicrobial potency with high selectivity and salt resistance
EP4344702A3 (en) Pyrazolyl derivatives useful as anti-cancer agents
WO2006017251A3 (en) Compositions for delivering peptide yy and pyy agonists
WO2004104018A3 (en) Compositions for delivering peptide yy and pyy agonists
EP4299118A3 (en) Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
WO1997018827A1 (en) Compositions and methods for the prevention and treatment of oral mucositis
KR20080064171A (en) Intranasal administration of rapid acting insulin
ZA200504804B (en) Topical anti-infective formulations
WO2007061829A3 (en) Pharmaceutical composition
US20080319072A1 (en) Composition and method for treating bacterial, viral, fungal diseases, inflammation and pain
IL194883A0 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol
EA200970274A1 (en) METHODS OF ADMINISTRATION OF HYPOGLYCEMIC MEANS WITH LONG TERM
CY1107819T1 (en) PHARMACEUTICAL FORM OF OLANZAPIN
WO2007146448A1 (en) Pharmaceutical formulations of glp-1 derivatives
Balkovec Section review: Anti-infectives: Lipopeptide antifungal agents
Khan et al. Suppression of hyphal formation and virulence of Candida albicans by natural and synthetic compounds
Yu et al. Self-assembly of antimicrobial peptide-based micelles breaks the limitation of trypsin
WO2024040027A3 (en) Phlip®-mediated delivery of sting agonists
TWI593704B (en) Anti-microbial peptide with effect of anti-pathogens and use thereof for drug preparation
RU2011133224A (en) NEW PHARMACEUTICAL COMPOSITIONS
US20070213270A1 (en) Peptide yy formulations having increased stability and resistance to microbial agents
JP2018507259A (en) Antimicrobial peptide
EP3519426B1 (en) Antimicrobial peptides comprising epsilon lysine residues
NO20055016L (en) Pharmaceutical composition as solid dosage form and method of preparation thereof
EP1996014B1 (en) Composition for treating bacterial, viral, fungal diseases, inflammation and pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23855593

Country of ref document: EP

Kind code of ref document: A2